Detail akcie Ginkgo Bio Rg-A online

Business Summary: Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Ginkgo Bioworks Holdings Inc revenues decreased 25% to $136.8M. Net loss decreased 47% to $232M. Revenues reflect Cell Engineering segment decrease of 23% to $106.7M, Biosecurity segment decrease of 32% to $30M, United States segment decrease of 33% to $103.4M. Lower net loss reflects Cell Engineering segment loss decrease of 57% to $78.3M, Biosecurity segment loss decrease of 29% to $14.9M.